Format

Send to

Choose Destination
J Vasc Interv Radiol. 2018 Sep 11. pii: S1051-0443(18)31330-7. doi: 10.1016/j.jvir.2018.07.006. [Epub ahead of print]

Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.

Author information

1
Department of Radiology, Saint-Eloi University Hospital, 80 avenue Augustin Fliche, Montpellier 34295, France.
2
Department of Nuclear Medicine, Guy de Chauliac University Hospital, Montpellier, France.
3
Department of Digestive Oncology, Saint-Eloi University Hospital, 80 avenue Augustin Fliche, Montpellier 34295, France.
4
Department of Hepatology, Saint-Eloi University Hospital, 80 avenue Augustin Fliche, Montpellier 34295, France.
5
Department of Nuclear Medicine, Guy de Chauliac University Hospital, Montpellier, France; PhyMedExp, INSERM U1046, CNRS UMR9214, University of Montpellier, Montpellier, France.
6
Department of Statistics and Epidemiology, University Hospital of Dijon, Dijon, France.
7
Department of Radiology, Saint-Eloi University Hospital, 80 avenue Augustin Fliche, Montpellier 34295, France; Montpellier Cancer Research Institute, INSERM U1194, Montpellier, France. Electronic address: B-guiu@chu-montpellier.fr.

Abstract

PURPOSE:

To identify predictive factors of tumor response, progression-free survival (PFS), overall survival (OS), and toxicity using three-dimensional (3D) voxel-based dosimetry in patients with intermediate and advanced stage hepatocellular carcinoma (HCC) treated by yttrium-90 (90Y) resin microspheres radioembolization (RE).

MATERIALS AND METHODS:

From February 2012 to December 2015, 45 90Y resin microspheres RE procedures were performed for HCC (Barcelona Clinic Liver Cancer stage B/C; n = 15/30). Area under the dose-volume histograms (AUDVHs) were calculated from 3D voxel-based dosimetry to measure 90Y dose deposition. Factors associated with tumor control (ie, complete/partial response or stable disease on Modified Response Evaluation Criteria in Solid Tumors) at 6 months were investigated. PFS and OS analyses were performed (Kaplan-Meier). Toxicity was assessed by occurrence of radioembolization-induced liver disease (REILD).

RESULTS:

Tumor control rate was 40.5% (17/42). Complete tumor targeting (odds ratio = 36.97; 95% confidence interval, 1.83-747; P < .001) and AUDVHtumor (odds ratio = 1.027; 95% confidence interval, 1.002-1.071; P = .033) independently predicted tumor control. AUDVHtumor ≥ 61 Gy predicted tumor control with 76.5% sensitivity and 75% specificity. PFS and OS in patients with incomplete tumor targeting were significantly shorter than in patients with complete tumor targeting (median PFS, 2.7 months [range, 0.8-4.6 months] vs 7.9 months [range, 2.1-39.5 months], P < .001; median OS, 4.5 months [range, 1.4-23 months] vs 19.2 months [range, 2.1-46.9 months], P < .001). Patients with incomplete tumor targeting and AUDVHtumor < 61 Gy, incomplete tumor targeting and AUDVHtumor > 61 Gy, complete tumor targeting and AUDVHtumor < 61 Gy, and AUDVHtumor > 61 Gy had median PFS of 2.7, 1.8, 6.3, and 12.1 months (P < .001). REILD (n = 4; 9.5%) was associated with higher dose delivered to normal liver (P = .04).

CONCLUSIONS:

Complete tumor targeting and 90Y dose to tumor are independent factors associated with tumor control and clinical outcomes.

PMID:
30217745
DOI:
10.1016/j.jvir.2018.07.006

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center